Skip to main content
. 2022 Feb 15;14(2):511–524. doi: 10.4251/wjgo.v14.i2.511

Table 3.

Univariate and multivariable analysis of patient and disease factors on overall survival in advanced esophageal cancer

Variable
Univariate

Multivariable1

Hazard ratio (95%CI)
P value
Hazard ratio (95%CI)
P value
Chemotherapy
Chemotherapy received vs not received
If 0 < time ≤ 10 mo2 - < 0.001 - < 0.001
If time > 10 mo 0.95 (0.88-1.03) 0.204 0.98 (0.86-1.11) 0.699
Age 1.01 (1.01-1.01) < 0.001 1.01 (1.00-1.01) < 0.001
Gender
Female 0.99 (0.96-1.02) 0.420 0.90 (0.86-0.95) < 0.001
Male 1 (reference) 1 (reference)
Race (combined)
Black 1.09 (1.05-1.14) < 0.001 1.02 (0.96-1.09) 0.457
Other 0.86 (0.82-0.91) < 0.001 0.87 (0.80-0.95) 0.002
White 1 (reference) 1 (reference)
Insurance type
Medicaid 1.28 (1.22-1.34) < 0.001 1.21 (1.13-1.31) < 0.001
Medicare 1.30 (1.26-1.33) < 0.001 1.04 (0.99-1.10) 0.119
Other government 1.15 (1.04-1.26) 0.006 0.95 (0.82-1.10) 0.493
Not insured 1.37 (1.29-1.45) < 0.001 1.20 (1.09-1.31) < 0.001
Private 1 (reference) 1 (reference)
Income quartiles for place of residence
$30000-$34999 0.94 (0.90-0.98) 0.007 Dropped out of the model
$35000-$45999 0.93 (0.90-0.97) < 0.001
$46000+ 0.87 (0.83-0.90) < 0.001
Less than $30000 1 (reference)
Treatment site
Academic 0.87 (0.85-0.89) < 0.001 0.91 (0.87-0.94) < 0.001
Non-academic 1 (reference) 1 (reference)
Geographic location in United States
Northeast 0.92 (0.89-0.96) < 0.001 0.96 (0.90-1.02) 0.180
Midwest 1.02 (0.98-1.06) 0.340 1.07 (1.01-1.14) 0.032
South 1.03 (0.99-1.07) 0.142 1.05 (0.99-1.11) 0.138
West 1 (reference) 1 (reference)
Residence area type
Metro 0.93 (0.86-1.01) 0.086 Dropped out of the model
Urban 0.95 (0.87-1.03) 0.193
Rural 1 (Reference)
Number of comorbidities
1 1.20 (1.17-1.24) < 0.001 1.09 (1.04-1.14) < 0.001
≥ 2 1.45 (1.37-1.52) < 0.001 1.16 (1.07-1.26) < 0.001
0 1 (reference) 1 (reference)
Year of diagnosis
2010-2014 0.99 (0.96-1.01) 0.286 Dropped out of the model
2004-2009 1 (Reference)
Grade
2 1.08 (1.00-1.18) 0.065 1.06 (0.95-1.20) 0.297
3 1.30 (1.20-1.41) < 0.001 1.28 (1.14-1.44) < 0.001
4 1.30 (1.15-1.48) < 0.001 1.21 (1.02-1.45) 0.032
1 1 (reference) 1 (reference)
AJCC T stage
pIS 0.57 (0.30-1.09) 0.090 1.11 (0.46-2.66) 0.821
T0 0.94 (0.69-1.26) 0.665 0.86 (0.59-1.25) 0.424
T1 0.88 (0.84-0.93) < 0.001 0.89 (0.84-0.95) < 0.001
T2 0.66 (0.62-0.69) < 0.001 0.69 (0.65-0.74) < 0.001
T3 0.65 (0.63-0.68) < 0.001 0.73 (0.70-0.76) < 0.001
T4 1 (reference) 1 (reference)
AJCC N stage
Positive 0.94 (0.91-0.97) < 0.001 Dropped out of the model
Negative 1 (reference)
1

12370 observations were used in the multivariable model.

2

As chemotherapy effect is not constant over time up to 10 mo, it was modeled with a time-dependent coefficient and the unadjusted hazard ratio for chemotherapy versus no chemotherapy is exp [-2.34 + 0.998 × log(time)] and adjusted hazard ratio is exp [-2.30 + 0.966 × log(time)].

AJCC: American Joint Committee on Cancer; CI: Confidence interval.